Status:
UNKNOWN
Assessment of Pupil Light Responses in Patients With Parkinson Disease
Lead Sponsor:
Sheba Medical Center
Conditions:
Parkinson Disease
Eligibility:
All Genders
30-75 years
Brief Summary
Parkinson diseases (PD) is the second most common degenerative disease of the central nervous system. The development of early diagnostic biomarkers may help identify at-risk individuals and allow pre...
Eligibility Criteria
Inclusion
- General inclusion criteria
- Age 30-75 years old
- Signed written informed consent
- Gender: Both (Male and Female)
- Pupillary reflex to light.
- Clear ocular media
- Patients'
- Patients with clinical presentations of the neurodegenerative forms of parkinsonism (bradykinesia, extrapyramidal rigidity, tremor, postural instability and gait disturbance) including: idiopathic Parkinson disease (PD), Lewy body disease (LBD), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD) and secondary parkinsonisms.
- Control group- inclusion criteria
- Normal eye examination
- Best-corrected visual acuity (BCVA) of 20/20
- Normal color vision test (Farnsworth/Lanthon D-15 Test)
- No present ocular disease
- No past ocular disease or surgery within last 6 months
- No use of any topical or systemic medications that could adversely influence efferent pupil movements
- Normal 24-2 Humphrey visual field and
- Short duration (≤10 minutes)
- Minimal fixation losses, False positive errors and False negative errors (less than 30% for each one of reliability indices)
Exclusion
- Diagnosis of dementia.
- Cognitive decline that may impair obtaining informed consent.
- Tremor or dyskinesia that could interfere with ophthalmic evaluation
- History of past (last 3 months) or present ocular disease or ocular surgery
- Use of any topical or systemic medications that could adversely influence pupillary reflex
- Psychiatric illness, active psychosis.
- Previous neurosurgical interventions, including stereotactic neurosurgical procedures.
- Past or current strokes or brain injury and other brain disorders (except PD/parkinsonism for patient group)
- Anti-dopaminergic drugs.
- Intolerance to gonioscopy, slit lamp examination, Goldmann applanation tomometry or other schedule study procedure.
- Visual media opacity including cloudy corneas.
- Any condition preventing accurate measurement or examination of the pupil.
Key Trial Info
Start Date :
November 20 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04117555
Start Date
November 20 2019
End Date
December 31 2024
Last Update
November 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Goldschleger Eye Research Institute, Sheba Medical Center,
Tel Litwinsky, Israel, 52621